Stan Jordan

List of Publications by Year
in descending order

318 papers	15,228 citations	18482 62 h-index	24258 110 g-index
330 all docs	330 docs citations	330 times ranked	9598 citing authors

#	Article	IF	Citations
1	Obinutuzumab for Desensitization: An Unexpected Benefit?. Transplantation, 2022, 106, 245-247.	1.0	1
2	Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. American Journal of Transplantation, 2022, 22, 691-697.	4.7	26
3	Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients. Transplantation, 2022, 106, e90-e91.	1.0	3
4	Evaluation of Clazakizumab (Antiâ€“Interleukin-6) in Patients WithÂTreatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. Kidney International Reports, 2022, 7, 720-731.	0.8	23
5	Use of a donorâ€derived cellâ€free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection. Pediatric Transplantation, 2022, 26, e14258.	1.0	9
6	Assessment of humoral and cellular immune responses to SARS CoVâ€2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Transplant Infectious Disease, 2022, 24, e13813.	1.7	12
7	Viralâ€specific cytotoxic Tâ€cell responses in HLAâ€sensitized kidney transplant patients maintained on everolimus and lowâ€dose tacrolimus. Transplant Infectious Disease, 2022, 24, .	1.7	1
8	HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates. Transplantation Direct, 2022, 8, e1312.	1.6	2
9	Donor-derived cell-free DNA in kidney transplantation: evolving concepts and potential limitations. Kidney International, 2022, 101, 676-677.	5.2	2
10	Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. American Journal of Transplantation, 2022, 22, 1133-1144.	4.7	18
11	US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response. Clinical Infectious Diseases, 2022, 75, 1940-1949.	5.8	3
12	Intravenous immunoglobulin contains high-titer neutralizing IgG antibodies to SARS-CoV-2. American Journal of Transplantation, 2022, 22, 2484-2485.	4.7	5
13	Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clinical Transplantation, 2022, 36, .	1.6	7
14	Diminished T-cell Immune Responses to SARS-CoV-2 Omicron Variant after BNT162b2 Vaccination. Immunology Letters, 2022, , .	2.5	0
15	Reply to Olivera and Mallat. Clinical Infectious Diseases, 2021, 73, e272-e273.	5.8	0
16	Trajectories of glomerular filtration rate and progression to end stage kidney disease afterÂkidney transplantation. Kidney International, 2021, 99, 186-197.	5.2	40
17	Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. Transplantation, 2021, 105, 436-442.	1.0	3
18	Donorâ€derived cellâ€free DNA (ddâ€cfDNA) for detection of allograft rejection in pediatric kidney transplants. Pediatric Transplantation, 2021, 25, e13850.	1.0	22

#	Article	IF	Citations
19	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. Journal of the American Society of Nephrology: JASN, 2021, 32, 397-409.	6.1	40
20	Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. American Journal of Transplantation, 2021, 21, 1612-1621.	4.7	11
21	Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. Current Transplantation Reports, 2021, 8, 127-139.	2.0	31
22	Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clinical and Experimental Immunology, 2021, 204, 310-320.	2.6	62
23	Imlifidase as a Potential Treatment for Antibody-Mediated Rejection. Current Transplantation Reports, 2021, 8, 157-161.	2.0	0
24	Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study. International Journal of Infectious Diseases, 2021, 105, 245-251.	3.3	13
25	Rationalizing Incompatible Living Donor Kidney Transplantation for Highly Sensitized Candidates. Current Transplantation Reports, 2021, 8, 250.	2.0	0
26	Association between ddâ€¢cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort. Clinical Transplantation, 2021, 35, e14402.	1.6	5
27	Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients. Transplantation, 2021, 105, 1818-1824.	1.0	14
28	Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). Transplantation, 2021, 105, 1808-1817.	1.0	54
29	Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. American Journal of Transplantation, 2021, 21, 3907-3918.	4.7	43
30	Development of CMVâ€šspecific cytotoxic T cells (CMVâ€Tc) in pediatric renal transplant recipients with CMV viremia. Pediatric Transplantation, 2021, 25, e14119.	1.0	1
31	Use of Rituximab for persistent EBV DNAemia, and Its effect on donorâ€šspecific antibody development in pediatric renal transplant recipients: A case series. Pediatric Transplantation, 2021, 25, e14113.	1.0	5
32	T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cellular and Molecular Immunology, 2021, 18, 2554-2556.	10.5	72
33	Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. Translational Research, 2021, 235, 48-61.	5.0	7
34	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. The Lancet Digital Health, 2021, 3, e795-e805.	12.3	25
35	Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests. Transplantation, 2021, 105, e272-e273.	1.0	2
36	Approach to Highly Sensitized Kidney Transplant Candidates and a Positive Crossmatch. Advances in Chronic Kidney Disease, 2021, 28, 587-595.	1.4	2

#	Article	IF	Citations
37	Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 109-116.	4.5	42
38	Impact of Tocilizumab (Antiâ€“IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection. Transplantation, 2020, 104, 856-863.	1.0	56
39	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
40	Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics. Transplantation, 2020, 104, 17-23.	1.0	12
41	Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients. Transplantation, 2020, 104, 1500-1507.	1.0	14
42	Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro. Transplantation, 2020, 104, 1574-1579.	1.0	26
43	Interleukin-6: An Important Mediator of Allograft Injury. Transplantation, 2020, 104, 2497-2506.	1.0	41
44	Obinutuzumab is Effective forÂthe Treatment of Refractory Membranous Nephropathy. Kidney International Reports, 2020, 5, 1515-1518.	0.8	37
45	Tocilizumab for Covid-19 â€" The Ongoing Search for Effective Therapies. New England Journal of Medicine, 2020, 383, 2387-2388.	27.0	36
46	The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 42-56.	4.7	27
47	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings, 2020, 52, 2711-2714.	0.6	33
48	Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. Clinical Infectious Diseases, 2020, 71, 3168-3173.	5.8	73
49	Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. American Journal of Transplantation, 2020, 20, 2581-2588.	4.7	20
50	CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377). Transplantation, 2020, 104, S67-S68.	1.0	3
51	Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone. Transplantation Direct, 2020, 6, e580.	1.6	12
52	Evolving Approaches to Treatment of Allosensitization and Antibody-Mediated Rejection. , 2020, , 177-189.		0
53	THE USE OF DD-CFDNA AS A PREDICTIVE TOOL FOR FUTURE PROTEINURIA. Transplantation, 2020, 104, S130-S130.	1.0	0
54	Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. American Journal of Transplantation, 2019, 19, 381-390.	4.7	25

#	Article	IF	Citations
55	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American Journal of Transplantation, 2019, 19, 3035-3045.	4.7	44
56	Clinical and Public Policy Implications of Pre-Formed DSA and Transplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 972-974.	4.5	1
57	Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?. Clinical Transplantation, 2019, 33, e13751.	1.6	48
58	Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients. Journal of the American Heart Association, 2019, 8, e010570.	3.7	33
59	Allocation of the Highest Quality Kidneys and Transplant Outcomes Under the New Kidney Allocation System. American Journal of Kidney Diseases, 2019, 73, 605-614.	1.9	24
60	Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 1663-1670.	4.7	124
61	Immune response to non-HLA antigens and renal allograft loss. Lancet, The, 2019, 393, 854-856.	13.7	5
62	Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. Transplantation, 2019, 103, 2666-2674.	1.0	19
63	Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection. Transplantation, 2019, 103, 262-272.	1.0	28
64	Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation. Transplantation, 2019, 103, 1763-1775.	1.0	32
65	A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. American Journal of Transplantation, 2018, 18, 2955-2964.	4.7	70
66	Immunoglobulin Gâ€“Degrading Enzyme of Streptococcus pyogenes (IdeS), Desensitization, and the Kidney Allocation System. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 799-801.	4.5	7
67	Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study. American Journal of Transplantation, 2018, 18, 650-658.	4.7	11
68	Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients. Transplantation Direct, 2018, 4, e379.	1.6	84
69	Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Failure in a Liver Transplant Patient: A Case Report. Transplantation Proceedings, 2018, 50, 4038-4041.	0.6	9
70	Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney International, 2017, 91, 729-737.	5.2	77
71	Assessment of Tocilizumab (Antiâ€“Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. American Journal of Transplantation, 2017, 17, 2381-2389.	4.7	278
72	Cell-Free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2017, 28, 2221-2232.	6.1	365

#	Article	IF	Citations
73	Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection. Transplantation, 2017, 101, 32-44.	1.0	215
74	The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis. American Journal of Transplantation, 2017, 17, 3123-3130.	4.7	25
75	Tocilizumab (Anti-IL-6R) Suppressed TNFÎ± Production by Human Monocytes in an In Vitro Model of Anti-HLA Antibody-Induced Antibody-Dependent Cellular Cytotoxicity. Transplantation Direct, 2017, 3, e139.	1.6	11
76	Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients. Transplantation, 2017, 101, 883-889.	1.0	25
77	Update on the use of immunoglobulin in human disease: AÂreview of evidence. Journal of Allergy and Clinical Immunology, 2017, 139, S1-S46.	2.9	454
78	Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization. Transplant Immunology, 2017, 45, 59-64.	1.2	5
79	Risk factors for the development of antibodyâ€mediated rejection in highly sensitized pediatric kidney transplant recipients. Pediatric Transplantation, 2017, 21, e13042.	1.0	4
80	Outcomes of Highly Sensitized Patients Undergoing Simultaneous Liver and Kidney Transplantation: A Single-Center Experience With Desensitization. Transplantation Proceedings, 2017, 49, 1394-1401.	0.6	4
81	IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. New England Journal of Medicine, 2017, 377, 442-453.	27.0	257
82	Clinical and histopathologic features of antibodyâ€mediated rejection among pediatric renal transplant recipients with preformed vs de novo donorâ€specific antibodies. Pediatric Transplantation, 2017, 21, e13079.	1.0	6
83	Desensitization: Overcoming the Immunologic Barriers to Transplantation. Journal of Immunology Research, 2017, 2017, 1-11.	2.2	67
84	Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. Journal of Immunology Research, 2017, 2017, 1-24.	2.2	28
85	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. journal of applied laboratory medicine, The, 2017, 2, 309-321.	1.3	59
86	Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection. Transplantation, 2017, 101, 2419-2428.	1.0	47
87	Liver Transplantation in a Patient With CD40 Ligand Deficiency and Hyper-IgM Syndrome: Clinical and Immunological Assessments. American Journal of Transplantation, 2016, 16, 1626-1632.	4.7	9
88	Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients. Transplantation Proceedings, 2016, 48, 806-808.	0.6	12
89	Progress in Desensitization of the Highly HLA Sensitized Patient. Transplantation Proceedings, 2016, 48, 802-805.	0.6	9
90	Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. Transplant Immunology, 2016, 38, 84-92.	1.2	29

#	Article	IF	Citations
91	Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transplant International, 2016, 29, 1276-1285.	1.6	38
92	Novel role of Vav1-Rac1 pathway in actin cytoskeleton regulation in interleukin-13-induced minimal change-like nephropathy. Clinical Science, 2016, 130, 2317-2327.	4.3	8
93	Risk factors associated with the development of histocompatibility leukocyte antigen sensitization. Current Opinion in Organ Transplantation, 2016, 21, 447-452.	1.6	4
94	T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1360-1368.	4.5	23
95	Potential Roles for C1 Inhibitor in Transplantation. Transplantation, 2016, 100, 1415-1424.	1.0	39
96	Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. New England Journal of Medicine, 2016, 374, 940-950.	27.0	279
97	Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients. Journal of the American Society of Nephrology: JASN, 2016, 27, 6-8.	6.1	6
98	A Phase I/II Trial of the Interleukin-6 Receptorâ€“Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation, 2015, 99, 2356-2363.	1.0	159
99	<scp>JC</scp> polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigenâ€sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transplant Infectious Disease, 2015, 17, 838-847.	1.7	13
100	Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. Transplantation, 2015, 99, 1423-1430.	1.0	61
101	Genetic Interactions Between TRPC6 and NPHS1 Variants Affect Posttransplant Risk of Recurrent Focal Segmental Glomerulosclerosis. American Journal of Transplantation, 2015, 15, 3229-3238.	4.7	17
102	Combined Lung-Kidney Transplantation: An Analysis of the UNOS/OPTN Database. American Surgeon, 2015, 81, 1047-1052.	0.8	16
103	Kidney transplantation in highly sensitized patients. British Medical Bulletin, 2015, 114, 113-125.	6.9	63
104	Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection. Transplant Immunology, 2015, 32, 9-17.	1.2	24
105	A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients. Transplantation, 2015, 99, 299-308.	1.0	128
106	Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy, 2015, 7, 377-398.	2.0	22
107	Modern approaches to incompatible kidney transplantation. World Journal of Nephrology, 2015, 4, 354.	2.0	25
108	Strategies to Improve Novel Drug Development in Kidney Transplantation Through the Clinical Trials Process. Clinical Transplants, 2015, 31, 163-172.	0.2	0

#	Article	IF	Citations
109	Immunologic and Infectious Complications in Highly Sensitized Patients Post-Kidney Transplantation. Clinical Transplants, 2015, 31, 265-273.	0.2	1
110	Transplantation in highly HLA-sensitized patients: challenges and solutions. Transplant Research and Risk Management, 2014, , 99.	0.7	1
111	Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clinical Transplantation, 2014, 28, 546-553.	1.6	31
112	Antiâ€“Interleukin 6 Receptor Antibodies Attenuate Antibody Recall Responses in a Mouse Model of Allosensitization. Transplantation, 2014, 98, 1262-1270.	1.0	59
113	Donor-specific antibodies in allograft recipients. Current Opinion in Organ Transplantation, 2014, 19, 591-597.	1.6	41
114	Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients. Transplantation, 2014, 98, 312-319.	1.0	111
115	Regulation of Anti-HLA Antibody-Dependent Natural Killer Cell Activation by Immunosuppressive Agents. Transplantation, 2014, 97, 294-300.	1.0	31
116	Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy. Clinical and Experimental Immunology, 2014, 178, 48-51.	2.6	8
117	The Authorsâ€™ Reply. Transplantation, 2014, 98, e8-e9.	1.0	0
118	7thInternational Immunoglobulin Conference: Foreword. Clinical and Experimental Immunology, 2014, 178, 1-2.	2.6	10
119	7thInternational Immunoglobulin Conference: Transplantation. Clinical and Experimental Immunology, 2014, 178, 46-47.	2.6	1
120	7thInternational Immunoglobulin Conference: Transplantation. Clinical and Experimental Immunology, 2014, 178, 64-64.	2.6	2
121	Immunoglobulins: current understanding and future directions. Clinical and Experimental Immunology, 2014, 178, 163-168.	2.6	13
122	Quantifying the Risk of Incompatible Kidney Transplantation: A Multicenter Study. American Journal of Transplantation, 2014, 14, 1573-1580.	4.7	157
123	Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab. Transplantation, 2014, 97, 755-761.	1.0	26
124	Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transplant Immunology, 2013, 28, 138-143.	1.2	41
125	Donor-specific HLA antibodies and renal allograft failure. Nature Reviews Nephrology, 2013, 9, 130-131.	9.6	30
126	Defining the Benefits of Desensitization Therapy. Transplantation, 2013, 95, e31-e32.	1.0	5

#	Article	IF	Citations
127	Efficacy, Outcomes, and Cost-Effectiveness of Desensitization Using IVIG and Rituximab. Transplantation, 2013, 95, 852-858.	1.0	99
128	Anti-CD3ÏµÌ induces splenic B220 lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization. International Immunology, 2012, 24, 529-538.	4.0	4
129	Significant Reduction of ATP Production in PHA-Activated CD4+ Cells in 1-Day-Old Blood from Transplant Patients. Transplantation, 2012, 94, 1243-1249.	1.0	10
130	Advancing kidney transplantation. Expert Review of Clinical Immunology, 2012, 8, 591-593.	3.0	0
131	The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nature Reviews Nephrology, 2012, 8, 348-357.	9.6	321
132	IFNÎ³ production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens. Transplant Immunology, 2012, 26, 107-112.	1.2	24
133	Complement fixing donorâ€specific antibodies and allograft loss. Pediatric Transplantation, 2012, 16, 1-3.	1.0	3
134	Desensitization Offers Hope to Highly HLA-Sensitized Patients for a Longer Life Expectancy After Incompatible Kidney Transplant. American Journal of Kidney Diseases, 2012, 59, 758-760.	1.9	8
135	Desensitizing the Broadly Human Leukocyte Antigenâ€“Sensitized Patient Awaiting Deceased Donor Kidney Transplantation. Transplantation Proceedings, 2012, 44, 60-61.	0.6	10
136	Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discovery Medicine, 2012, 13, 235-45.	0.5	13
137	Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discovery Medicine, 2012, 13, 267-73.	0.5	14
138	Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transplant Immunology, 2011, 24, 142-148.	1.2	16
139	B-cell immunotherapeutics. Current Opinion in Organ Transplantation, 2011, 16, 416-424.	1.6	37
140	Antibody Testing Strategies for Deceased Donor Kidney Transplantation After Immunomodulatory Therapy. Transplantation, 2011, 92, 48-53.	1.0	29
141	Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients. American Journal of Transplantation, 2011, 11, 196-202.	4.7	153
142	Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clinical and Experimental Nephrology, 2011, 15, 164-170.	1.6	18
143	Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Review of Clinical Immunology, 2011, 7, 341-348.	3.0	52
144	Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2894-2900.	4.5	82

#	Article	IF	Citations
145	Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients. Transplantation, 2010, 90, 1473-1477.	1.0	180
146	Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation. Transplantation, 2010, 89, 1095-1102.	1.0	213
147	Advances in diagnosing and managing antibody-mediated rejection. Pediatric Nephrology, 2010, 25, 2035-2048.	1.7	68
148	Is Rituximab Safe to Use in Kidney Transplant Patients?. American Journal of Transplantation, 2010, 10, 8-9.	4.7	10
149	Transplant Immunology. , 2010, , 356-363.		0
150	Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2207-2212.	4.5	177
151	Intracellular IFNÎ³ production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization. Transplant Immunology, 2010, 22, 121-127.	1.2	10
152	Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplant Immunology, 2010, 23, 117-120.	1.2	8
153	Cellular allo reactivity against paternal HLA antigens in normal multiparous females as detected by intracellular cytokine flow cytometry remains elevated over years despite diminution of anti-HLA antibody levels. Transplant Immunology, 2010, 23, 133-140.	1.2	7
154	In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction. Transplant Immunology, 2010, 23, 170-173.	1.2	5
155	Acute Hemolysis After High-Dose Intravenous Immunoglobulin Therapy in Highly HLA Sensitized Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1993-1997.	4.5	113
156	Modelling the response of a standing person to the slipstream generated by a passenger train. Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit, 2009, 223, 567-579.	2.0	13
157	Therapeutic plasma exchange for desensitization prior to transplantation in ABOâ€incompatible renal allografts. Journal of Clinical Apheresis, 2009, 24, 155-160.	1.3	25
158	Intravenous immunoglobulin as treatment for BK virus: Nephropathy. Pediatric Transplantation, 2009, 13, 11-13.	1.0	13
159	Intravenous Immunoglobulin a Natural Regulator of Immunity and Inflammation. Transplantation, 2009, 88, 1-6.	1.0	102
160	Design Considerations for Micro- and Nanopositioning: Leveraging the Latest for Biophysical Applications. Current Pharmaceutical Biotechnology, 2009, 10, 515-521.	1.6	8
161	Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and Rituximab. American Journal of Transplantation, 2008, 8, 144-149.	4.7	57
162	Outcome of management strategies for BK virus replication in pediatric renal transplant recipients. Pediatric Transplantation, 2008, 12, 180-186.	1.0	22

#	Article	IF	Citations
163	Clinical significance of peripheral blood Epsteinâ€“Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatric Transplantation, 2008, 12, 778-784.	1.0	29
164	Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization. Transplant Immunology, 2008, 19, 178-186.	1.2	11
165	Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation. New England Journal of Medicine, 2008, 359, 242-251.	27.0	624
166	A study of the slipstreams of high-speed passenger trains and freight trains. Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit, 2008, 222, 177-193.	2.0	94
167	Therapeutic Strategies in Management of the Highly HLA-Sensitized and ABO-Incompatible Transplant Recipients. Contributions To Nephrology, 2008, 162, 13-26.	1.1	38
168	Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization Therapy. Transplantation, 2008, 86, 820-825.	1.0	122
169	Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrology Dialysis Transplantation, 2007, 23, 377-380.	0.7	36
170	Overexpression of Interleukin-13 Induces Minimal-Changeâ€“Like Nephropathy in Rats. Journal of the American Society of Nephrology: JASN, 2007, 18, 1476-1485.	6.1	192
171	Desensitization protocols for crossing human leukocyte antigen and ABO incompatible barriers. Current Opinion in Organ Transplantation, 2007, 12, 371-378.	1.6	4
172	14th International HLA and Immunogenetics Workshop: Report on understanding antibodies in transplantation. Tissue Antigens, 2007, 69, 160-173.	1.0	33
173	The onset of rapidly progressive neurologic deterioration after a brief gastrointestinal illness in a renal allograft recipient. Transplant Infectious Disease, 2007, 9, 142-147.	1.7	7
174	Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis. Rheumatology International, 2007, 27, 655-660.	3.0	9
175	Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatric Nephrology, 2007, 22, 2059-2065.	1.7	65
176	Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 844-852.	4.5	71
177	Adenovirus mediated IL-10 gene transfer to the airway of the rat lung for prevention of lung allograft rejection. Transplant Immunology, 2006, 16, 95-98.	1.2	18
178	Transplantation of the highly human leukocyte antigenâ€“sensitized patient: long-term outcomes and future directions. Transplantation Reviews, 2006, 20, 146-156.	2.9	14
179	344 OVEREXPRESSION OF INTERLEUKIN-13 INDUCES MINIMAL CHANGE-LIKE NEPHROPATHY IN RATS AND IS ASSOCIATED WITH INCREASED B7-1 EXPRESSION IN THE GLOMERULI.. Journal of Investigative Medicine, 2006, 54, S139.3-S139.	1.6	1
180	Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy. Clinical Transplantation, 2006, 20, 289-294.	1.6	27

#	Article	IF	Citations
181	Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. American Journal of Transplantation, 2006, 6, 459-466.	4.7	148
182	Effect of Induction Therapy Protocols on Transplant Outcomes in Crossmatch Positive Renal Allograft Recipients Desensitized with IVIG. American Journal of Transplantation, 2006, 6, 2384-2390.	4.7	53
183	Presensitization: The Problem and Its Management. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 421-432.	4.5	104
184	Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Transactions of the American Clinical and Climatological Association, 2006, 117, 199-211; discussion 211.	0.5	29
185	Co-infection of Polyomavirus-BK and Cytomegalovirus in Renal Transplant Recipients. Transplantation, 2005, 80, 198-205.	1.0	63
186	Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatric Transplantation, 2005, 9, 155-161.	1.0	43
187	Current approaches to treatment of antibody-mediated rejection. Pediatric Transplantation, 2005, 9, 408-415.	1.0	93
188	Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transplant Infectious Disease, 2005, 7, 71-74.	1.7	75
189	Cellular Immune Responses to Cytomegalovirus in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 110-117.	4.7	86
190	Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatric Nephrology, 2005, 20, 1376-1381.	1.7	61
191	Cyclosporine-sparing effects of daclizumab in renal allograft recipients. American Journal of Health-System Pharmacy, 2005, 62, 391-396.	1.0	5
192	Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 3256-3262.	6.1	397
193	Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome. Pediatric Nephrology, 2004, 19, 627-632.	1.7	72
194	Consensus Opinion from the Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-Mediated Rejection and Desensitization Protocols. Transplantation, 2004, 78, 181-185.	1.0	90
195	Immunomodulatory Effects of Combination of Pooled Human Gammaglobulin and Rapamycin on Cell Proliferation and Apoptosis in the Mixed Lymphocyte Reaction. Transplantation, 2004, 78, 1134-1138.	1.0	15
196	Pooled Human Gammaglobulin Modulates Surface Molecule Expression and Induces Apoptosis in Human B Cells. American Journal of Transplantation, 2003, 3, 156-166.	4.7	78
197	Utility of Intravenous Immune Globulin in Kidney Transplantation: Efficacy, Safety, and Cost Implications. American Journal of Transplantation, 2003, 3, 653-664.	4.7	126
198	Fabry Disease in a Renal Allograft. American Journal of Transplantation, 2003, 3, 1030-1032.	4.7	13

#	Article	IF	Citations
199	Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. American Journal of Kidney Diseases, 2003, 42, 1114-1120.	1.9	121
200	Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-Î± production. Clinical and Experimental Immunology, 2003, 134, 111-119.	2.6	14
201	Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients1. Transplantation, 2003, 76, 631-636.	1.0	219
202	Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation1. Transplantation, 2003, 76, 348-353.	1.0	93
203	Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clinical Transplants, 2003, , 193-8.	0.2	5
204	IMPACT OF HEPATITIS B CORE ANTIBODY STATUS ON OUTCOMES OF CADAVERIC RENAL TRANSPLANTATION. Transplantation, 2002, 73, 85-89.	1.0	53
205	Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. Transplantation, 2002, 74, 1648-1651.	1.0	4
206	Transient cold preservation alone stimulates tumor necrosis factor-Î± gene expression in a model of rat syngeneic lung transplantation. Transplantation Proceedings, 2002, 34, 1111-1113.	0.6	0
207	Treatment of Parvovirus B-19 (PV B-19) Infection Allows for Successful Kidney Transplantation Without Disease Recurrence. American Journal of Transplantation, 2002, 2, 425-428.	4.7	36
208	Treatment of Active Cytomegalovirus Disease with Oral Ganciclovir in Renal Allograft Recipients: Monitoring Efficacy with Quantitative Cytomegalovirus Polymerase Chain Reaction. American Journal of Transplantation, 2002, 2, 671-673.	4.7	6
209	Management of the Highly HLA- Sensitized Patient. A Novel Role for Intravenous Gammaglobulin. American Journal of Transplantation, 2002, 2, 691-692.	4.7	27
210	Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, Î³-IFN and IL-4) in vitro. Transplant Immunology, 2001, 9, 1-6.	1.2	10
211	CYCLOSPORINE MICROEMULSION??? AND MYCOPHENOLATE MOFETIL???RELATED LYMPHOID AGGREGATES ARE NOT ASSOCIATED WITH ACUTE REJECTION. Transplantation, 2001, 72, 251-256.	1.0	5
212	PROLONGATION OF ALLOGRAFT SURVIVAL WITH VIRAL IL-10 TRANSFECTION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT HEART ALLOGRAFT REJECTION1. Transplantation, 2001, 71, 686-691.	1.0	46
213	Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney International, 2001, 59, 2126-2133.	5.2	186
214	Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney International, 2001, 59, 2126.	5.2	24
215	HYDROPHOBIC EXTRACTS OF A CHINESE HERB (CMX-13) EXHIBIT POTENT IMMUNOSUPPRESSIVE PROPERTIES AND PREVENT ACUTE REJECTION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT LUNG TRANSPLANTATION1. Transplantation, 2000, 70, 1094-1098.	1.0	2
216	Improvement in Lupus Nephritis Following Treatment With a Chinese Herbal Preparation. JAMA Pediatrics, 1999, 153, 850.	3.0	5

#	Article	IF	Citations
217	Expression of Î“-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clinical Transplantation, 1999, 13, 201-207.	1.6	42
218	Renal transplantation in infants and children. Indian Journal of Pediatrics, 1999, 66, 263-275.	0.8	0
219	Lung allograft dysfunction correlates with Î³-interferon gene expression in bronchoalveolar lavage. Journal of Heart and Lung Transplantation, 1999, 18, 627-636.	0.6	54
220	Antithrombin III inhibits T- and B-lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Transplantation Proceedings, 1999, 31, 816-817.	0.6	6
221	Decreased Î³-IFN and IL-2 gene expression in regional lymph nodes of skin allografts is associated with increased allograft survival in the WKY F344 rat model. Transplantation Proceedings, 1999, 31, 818-819.	0.6	0
222	Antithrombin III inhibits T and B lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Transplantation Proceedings, 1999, 31, 847-848.	0.6	9
223	THE CLINICAL SIGNIFICANCE OF ANTIBODIES TO HUMAN VASCULAR ENDOTHELIAL CELLS AFTER CARDIAC TRANSPLANTATION1. Transplantation, 1999, 67, 385-391.	1.0	101
224	ANTITHROMBIN III TREATMENT IMPROVES PARAMETERS OF ACUTE INFLAMMATION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT LUNG ALLOGRAFT REJECTION. Transplantation, 1999, 67, 526-528.	1.0	18
225	POOLED HUMAN GAMMAGLOBULIN (IVIG) INHIBITS THE MIXED LYMPHOCYTE REACTION (MLR) THROUGH MODULATION OF SURFACE MOLECULES ON ANTIGEN PRESENTING CELLS (APC). Transplantation, 1999, 67, S59.	1.0	1
226	Dacluzimab is Comparable to Antithymocyte Globulin (ATG) Induction in Preventing Acute Rejection (AR) Episodes in High Risk Renal Transplant Recipients. Transplantation, 1999, 67, S151.	1.0	1
227	IMMUNOLOGICAL CHARACTERIZATION OF ANTI-ENDOTHELIAL CELL ANTIBODIES INDUCED BY CYTOMEGALOVIRUS INFECTION1. Transplantation, 1999, 68, 1311-1318.	1.0	41
228	PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IS ASSOCIATED WITH REDUCED Th1 CYTOKINE RESPONSES IN THE WKY???F344 RAT MODEL. Transplantation, 1999, 68, 1393-1401.	1.0	16
229	PRELIMINARY RESULTS FROM A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL OF INTRAVENOUS GAMMAGLOBULIN (IVIG) + PULSE STEROIDS (PS) FOR THE TREATMENT OF ACUTE REJECTION (AR) EPISODES IN RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1999, 67, S117.	1.0	0
230	Nephronophthisis associated with Ellis-van Creveld syndrome. Pediatric Nephrology, 1998, 12, 20-22.	1.7	35
231	Pre-transplant donor-specific transfusions induce allograft rejection and IL-2 gene expression in the WKY â†' F344 functional tolerance model of rat lung transplantation. Transplant Immunology, 1998, 6, 137-146.	1.2	11
232	Immunosuppressive Effect of the Hydrophobic Extract of a Chinese Herb on Rat Lung Allograft Rejection. Transplantation Proceedings, 1998, 30, 980-981.	0.6	5
233	TOLERANCE INDUCTION BY INTRATHYMIC INOCULATION PREVENTS CHRONIC RENAL ALLOGRAFT REJECTION1,2. Transplantation, 1998, 65, 272-275.	1.0	11
234	POSTTRANSPLANT THERAPY USING HIGH-DOSE HUMAN IMMUNOGLOBULIN (INTRAVENOUS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 T RECIPIENTS AND POTENTIAL MECHANISM OF ACTION1. Transplantation, 1998, 66, 800-805.	1.0	238

#	Article	IF	Citations
235	A STABLE PROSTACYCLIN ANALOG, BERAPROST SODIUM, ATTENUATES PLATELET ACCUMULATION AND PRESERVATION-REPERFUSION INJURY OF ISOGRAFTS IN A RAT MODEL OF LUNG TRANSPLANTATION1. Transplantation, 1998, 66, 1132-1136.	1.0	18
236	PREVENTION AND PREEMPTIVE THERAPY OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER RECIPIENTS1. Transplantation, 1998, 66, 1604-1611.	1.0	314
237	Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatric Transplantation, 1998, 2, 92-105.	1.0	26
238	Selective expression of the interleukin-2 gene discriminates between the auto- and allo-mixed lymphocyte reaction. Transplant Immunology, 1997, 5, 35-38.	1.2	9
239	Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. Transplant Immunology, 1997, 5, 104-111.	1.2	68
240	CORRELATION OF CYTOMEGALOVIRUS DNA LEVELS WITH RESPONSE TO ANTIVIRAL THERAPY IN CARDIAC AND RENAL ALLOGRAFT RECIPIENTS1. Transplantation, 1997, 63, 957-963.	1.0	54
241	ACCUMULATION OF PLATELETS IN RAT SYNGENEIC LUNG TRANSPLANTS. Transplantation, 1997, 64, 801-806.	1.0	54
242	URETERITIS AND CHOLECYSTITIS. Transplantation, 1997, 64, 1071-1073.	1.0	31
243	LONG-TERM ALLOGRAFT ACCEPTANCE IN A PATIENT WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. Transplantation, 1997, 64, 1578-1582.	1.0	16
244	PARVOVIRUS B19 INFECTION-RELATED COMPLICATIONS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1997, 64, 1847-1850.	1.0	119
245	Induction of specific tolerance through mixed hematopoietic chimerism prevents chronic renal allograft rejection in a rat model. Surgery, 1996, 120, 213-220.	1.9	21
246	Donor-specific transfusions enhance the immunosuppressive effects of single-dose cyclosporine A and CTLA4-Ig but do not result in long-term graft acceptance in a histoincompatible model of rat lung allograft rejection. Transplant Immunology, 1996, 4, 33-37.	1.2	9
247	Delayed Development of Obliterative Bronchiolitis Syndrome With OKT3 After Unilateral Lung Transplantation. Chest, 1996, 109, 870-873.	0.8	31
248	SOLUBLE CTLA4Ig MODIFIES PARAMETERS OF ACUTE INFLAMMATION IN RAT LUNG ALLOGRAFT REJECTION WITHOUT ALTERING LYMPHOCYTIC INFILTRATION OR TRANSCRIPTION OF KEY CYTOKINES1. Transplantation, 1995, 59, 551-558.	1.0	26
249	ASSESSMENT OF PATHOLOGICAL CHANGES ASSOCIATED WITH CHRONIC ALLOGRAFT REJECTION AND TOLERANCE IN TWO EXPERIMENTAL MODELS OF RAT LUNG TRANSPLANTATION. Transplantation, 1995, 59, 1509-1516.	1.0	57
250	Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Journal of Clinical Immunology, 1995, 15, S76-S85.	3.8	18
251	Modification of the Senning repair in a case of transposition of the great arteries with juxtaposition of the atrial appendages. European Journal of Cardio-thoracic Surgery, 1995, 9, 50-51.	1.4	5
252	Treatment of Stevens-Johnson Syndrome With Pooled Human Intravenous Immune Globulin. Clinical Pediatrics, 1995, 34, 48-51.	0.8	23

#	Article	IF	Citations
253	Cytokine gene expression in rejecting and tolerant rat lung allograft models: analysis by RT-PCR. Transplant Immunology, 1995, 3, 151-161.	1.2	47
254	Alterations of the interleukin-4 pathway in production of tolerance by mixed hematopoietic chimerism*. Surgery, 1995, 118, 212-219.	1.9	7
255	Prevention Of Chronic Rejection And Graft Arteriosclerosis By Tolerance Induction. Transplantation, 1995, 59, 282-287.	1.0	64
256	Prevention Of Chronic Rejection And Graft Arteriosclerosis By Tolerance Induction. Transplantation, 1995, 59, 282-287.	1.0	3
257	Use of polymerase chain reaction to rapidly detect cytomegalovirus DNA in peripheral blood leukocytes of transplant recipients. Transplantation Proceedings, 1995, 27, 1272-3.	0.6	6
258	Soluble CTLA4Ig modifies acute rejection of rat lung allografts without blocking accumulation of key cytokine transcripts. Transplantation Proceedings, 1995, 27, 406-8.	0.6	5
259	Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. Journal of Clinical Immunology, 1994, 14, 178-189.	3.8	67
260	Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transplant Immunology, 1994, 2, 337-341.	1.2	42
261	INTRAVENOUS IMMUNOGLOBULIN SUPPRESSION OF HLA ALLOANTIBODY IN HIGHLY SENSITIZED TRANSPLANT CANDIDATES AND TRANSPLANTATION WITH A HISTOINCOMPATIBLE ORGAN. Transplantation, 1994, 57, 553-562.	1.0	220
262	GAMMA-INTERFERON GENE EXPRESSION IN HUMAN RENAL ALLOGRAFT FINE-NEEDLE ASPIRATES. Transplantation, 1994, 57, 498-501.	1.0	11
263	GAMMA-INTERFERON GENE EXPRESSION IN HUMAN RENAL ALLOGRAFT FINE-NEEDLE ASPIRATES. Transplantation, 1994, 57, 498-501.	1.0	45
264	Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clinical and Experimental Immunology, 1994, 97 Suppl 1, 31-8.	2.6	6
265	Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation, 1994, 57, 553-62.	1.0	45
266	Successful balloon dilatation of ascending vein stenosis in obstructed supracardiac total anomalous pulmonary venous connection. Pediatric Cardiology, 1994, 15, 78-80.	1.3	21
267	Modulation of MHC Expression on Human Endothelial Cells by Sera from Patients with Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology, 1993, 68, 321-326.	2.0	8
268	Immunocytologic Analysis of Cells Obtained from Bronchoalveolar Lavage in a Model of Rat Lung Allograft Rejection. Journal of Surgical Research, 1993, 55, 351-356.	1.6	17
269	THE PARTICIPATION OF TUMOR NECROSIS FACTOR IN THE PATHOGENESIS OF LUNG ALLOGRAFT REJECTION IN THE RAT. Transplantation, 1993, 55, 967-971.	1.0	30
270	Immunosuppression in organ transplantation. Seminars in Pediatric Surgery, 1993, 2, 206-7.	1.1	4

#	Article	IF	Citations
271	Treatment of Antineutrophil Cytoplasmic Autoantibody-Positive Systemic Vasculitis and Glomerulonephritis With Pooled Intravenous Gammaglobulin. American Journal of Kidney Diseases, 1992, 20, 504-508.	1.9	47
272	Vascular rejection and graft eosinophilia in rat lung allografts. Journal of Surgical Research, 1991, 51, 310-315.	1.6	13
273	Cell-Mediated Immunity in Patients on Hemodialysis: Relationship with Hepatitis B Carrier Status. American Journal of Nephrology, 1991, 11, 98-101.	3.1	10
274	STIMULUS-SPECIFIC 1,25(OH)2D3 MODULATION OF TNF AND IL-1-BETA GENE EXPRESSION IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS AND MONOCYTOID CELL LINES. Transplantation, 1991, 51, 498-502.	1.0	18
275	Inhibition of Protein-Kinase C in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus: Effect on Spontaneous Immunoglobulin Production. Autoimmunity, 1991, 10, 227-231.	2.6	2
276	Cytokine gene activation in rat lung allografts: analysis by northern blotting. Transplantation Proceedings, 1991, 23, 604-6.	0.6	10
277	Metabolic and Hematologic Effects and Immune Complex Formation Related to Pertussis Immunization. Pediatric Research, 1990, 27, 353-357.	2.3	15
278	Anti-vascular endothelial cell antibodies in severe preeclampsia. American Journal of Obstetrics and Gynecology, 1990, 162, 138-146.	1.3	100
279	A new percutaneous renal biopsy device for pediatric patients. Pediatric Nephrology, 1989, 3, 191-193.	1.7	17
280	1,25 Dihydroxyvitamin-D3 regulation of immunoglobulin production in peripheral blood mononuclear cells of patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 1989, 2, 861-867.	6.5	10
281	Intravenous Î³-globulin therapy in systemic lupus erythematosus and immune complex disease. Clinical Immunology and Immunopathology, 1989, 53, S164-S169.	2.0	69
282	1-Oleoyl-2-acetylglycerol promotes immunoglobulin production independent of cell proliferation in human peripheral blood mononuclear cells. Biochemical and Biophysical Research Communications, 1989, 161, 1319-1326.	2.1	1
283	Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: Relationship to clinical activity. Clinical Immunology and Immunopathology, 1988, 47, 354-362.	2.0	38
284	Anti-vascular endothelial cell antibodies in patients with IgA nephropathy: Frequency and clinical significance. Clinical Immunology and Immunopathology, 1988, 49, 450-462.	2.0	39
285	HYPERACUTE ALLOGRAFT REJECTION MEDIATED BY ANTI-VASCULAR ENDOTHELIAL CELL ANTIBODIES WITH A NEGATIVE MONOCYTE CROSSMATCH. Transplantation, 1988, 46, 585-586.	1.0	46
286	DETERMINATION OF ANTIIDIOTYPIC ANTIBODIES TO ANTI-HLA IgG FOLLOWING BLOOD TRANSFUSIONS. Transplantation, 1987, 44, 30-33.	1.0	19
287	Detection of bovine serum albumin in the circulating IgA immune complexes of patients with IgA nephropathy. Clinical Immunology and Immunopathology, 1987, 43, 395-402.	2.0	24
288	Plasma exchange improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients. Pediatric Nephrology, 1987, 1, 276-280.	1.7	22

#	Article	IF	Citations
289	Experience With Renal Transplantation in Children Undergoing Peritoneal Dialysis (CAPD/CCPD). American Journal of Kidney Diseases, 1986, 8, 181-185.	1.9	24
290	Petechiae and urticaria after DTP vaccination: Detection of circulating immune complexes containing vaccine-specific antigens. Journal of Pediatrics, 1986, 109, 1009-1012.	1.8	30
291	Postpartum Renal Failure in a Patient with Membranoproliferative Glomerulonephritis Type II. American Journal of Nephrology, 1986, 6, 382-385.	3.1	7
292	SPONTANEOUS ANTI-TUBULAR-BASEMENT-MEMBRANE ANTIBODY PRODUCTION BY LYMPHOCYTES ISOLATED FROM A REJECTED ALLOGRAFT. Transplantation, 1986, 41, 173-176.	1.0	12
293	SHORT-COURSE ANTITHYMOCYTE GLOBULIN FOR TREATMENT OF RENAL TRANSPLANT REJECTION IN CHILDREN. Transplantation, 1986, 41, 133-134.	1.0	4
294	Circulating immune complexes in Kawasaki syndrome. Pediatric Infectious Disease Journal, 1985, 4, 48-51.	2.0	45
295	Quantitation of circulating immune complexes in human serum by the Raji cell and F(abâ€²)2 anti-C3 micro enzyme immunoassays. Journal of Immunological Methods, 1985, 83, 363-370.	1.4	15
296	Induction of neonatal renal tubular dysfunction by transplacentally acquired IgG from a mother with SjÃ¶gren syndrome. Journal of Pediatrics, 1985, 107, 566-569.	1.8	19
297	1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. Journal of Immunology, 1985, 134, 3032-5.	0.8	200
298	Acute Bromate Poisoning Associated with Renal Failure and Deafness Presenting as Hemolytic Uremic Syndrome. American Journal of Nephrology, 1984, 4, 188-191.	3.1	26
299	1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells.. Journal of Clinical Investigation, 1984, 74, 657-661.	8.2	439
300	False-negative anti-DNA antibody activity in infantile systemic Lupus erythematosus (SLE). Journal of Clinical Immunology, 1984, 4, 156-162.	3.8	18
301	Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.. British Journal of Clinical Pharmacology, 1984, 18, 725-732.	2.4	8
302	Characterization of soluble circulating immune complexes by antigen-specific dissociation: Detection in the Raji cell radioimmune assay. Clinical Immunology and Immunopathology, 1983, 27, 357-368.	2.0	5
303	Continuous Ambulatory Peritoneal Dialysis Catheters in Children. Archives of Surgery, 1983, 118, 1398.	2.2	28
304	CADAVER RENAL TRANSPLANT OUTCOME IN RECIPIENTS WITH AUTOLYMPHOCYTOTOXIC ANTIBODIES. Transplantation, 1983, 35, 429-431.	1.0	30
305	Circulating Immune Complexes during Various Forms of Renal Allograft Rejection Episodes. Nephron, 1982, 31, 141-145.	1.8	0
306	Plasma inhibition of lymphocyte proliferation in nephrotic syndrome: Correlation with hyperlipidemia. Journal of Clinical Immunology, 1982, 2, 276-281.	3.8	17

#	Article	IF	Citations
307	AUTOLYMPHOCYTOTOXIC ANTIBODIES IN PATIENTS ON DIALYSIS AWAITING RENAL TRANSPLANTATION. Transplantation, 1981, 32, 248-251.	1.0	11
308	941 PLASMA INHIBITION OF LYMPHOCYTE BLASTOGENESIS IN NEPHROTIC SYNDROME: CORRELATION WITH HYPERLIPIDEMIA. Pediatric Research, 1981, 15, 599-599.	2.3	0
309	CIRCULATING IMMUNE COMPLEXES IN PEDIATRIC RENAL ALLOGRAFT REJECTION. Transplantation, 1981, 31, 190-194.	1.0	9
310	Studies of Immune-Complex Glomerulonephritis Mediated by Human Thyroglobulin. New England Journal of Medicine, 1981, 304, 1212-1215.	27.0	87
311	Circulating Immune Complexes in Patients with Cystic Fibrosis. Chest, 1981, 80, 405-411.	0.8	26
312	DEMONSTRATION OF CIRCULATING IMMUNE COMPLEXES (CICs) CONTAINING HUMAN THYROGLOBULIN (HuTg) IN A PATIENT WITH IMMUNE COMPLEX GLOMERULONEPHRITIS (ICGN) MEDIATED BY THYROGLOBULIN ANTI-THYROGLOBULIN IMMUNE COMPLEXES. Pediatric Research, 1980, 14, 1013-1013.	2.3	0
313	ACCELERATED ACUTE REJECTION OF PRIMARY RENAL ALLOGRAFTS IN PEDIATRIC PATIENTS. Transplantation, 1980, 30, 5-8.	1.0	7
314	Hepatitis B infection in pediatric dialysis and transplant patients: Significance of e antigen. Journal of Pediatrics, 1980, 97, 550-553.	1.8	6
315	Chronic pericardial constriction with effusion in childhood.. Archives of Disease in Childhood, 1979, 54, 890-895.	1.9	8
316	Pancreatitis in children and adolescents. Journal of Pediatrics, 1977, 91, 211-216.	1.8	77
317	Rituximab: An emerging therapeutic agent for kidney transplantation. Transplant Research and Risk Management, 0, Volume 1, 15-29.	0.7	8
318	Therapies for the Allosensitized Patient. , 0, , 95-102.		0